Skip to the page content
Check before you give

Subcutaneous Drug Development & Delivery Consortium Inc

EIN 85-0837695 · Beaverton, OR

Public records raise at least one point you should look into before giving.

LegitimacyCautionRegistration and standingFinancial healthNot ratedToo small or too little detailGovernanceNot ratedToo small or too little detailImpact evidenceDescribes programsHow well its results are evidenced

What it says it does

OUR MISSION IS TO COLLABORATIVELY ADVANCE THE MOST PRESSING ISSUES AND OPPORTUNITIES IN SUBCUTANEOUS DOSAGE AND DELIVERY IN A PRECOMPETITIVE MANNER.

Income
$1.0 million
Spending
$862,745
Employees
0
Volunteers
4

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. How we rate

Financial health

We do not score finances when yearly spending is very small or the return has too little detail. The ratios stop meaning much at that size.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. How we rate

Governance

This return does not answer enough of the governance questions to score.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (1)
  1. A.PATIENT PREFERENCE & EXPERIENCE: COMPLETED THE DESIGN AND DEVELOPMENT OF THE CONJOINT TOOL AND SURVEY ON PATIENT PREFERENCE FOR SUBCUTANEOUS DRUG DELIVERY; FIELDING IS COMPLETE WITH OVER 500 RESPONSES RECORDED FROM THE US, EU, AND JAPAN, AND ANALYSIS IS UNDERWAY. B.HIGH DOSE HIGH VOLUME: COMPLETED AN INDUSTRY-WIDE SURVEY ON "HARMONIZATION OF PAIN METHODOLOGIES FOR SC ADMINISTRATION-; DRAFT MANUSCRIPT "INTEGRATED CMC ROAD MAP FOR DEVELOPMENT OF HDHV PRODUCTS- AND THE "HDHV SELECTION CRITERIA MATRIX" ARE EXPECTED TO BE PUBLISHED IN 2026 FOLLOWING INTERNAL SC CONSORTIUM REVIEW. C.CLINICAL DESIGN & REGULATORY STRATEGY: PUBLISHED A CROSS-COMPANY SURVEY MANUSCRIPT ON CLINICAL AND REGULATORY STRATEGY IN THE JOURNAL OF CONTROLLED RELEASE AND CONDUCTED A WORKSHOP ON "DEVELOPMENT PATHWAYS AND CONSIDERATIONS FOR SUBCUTANEOUS BIOLOGIC FORMULATIONS" AT THE CRS 2025 ANNUAL MEETING & EXPOSITION IN PHILADELPHIA. D.SUSTAINABILITY: COMPLETED AND PRESENTED RESULTS OF THE INDUSTRY BENCHMARKING SURVEY AT MULTIPLE CONFERENCES THROUGHOUT THE YEAR, INCLUDING A POSTER PRESENTATION AT THE PDA UPS CONFERENCE IN VIENNA, AND SUBMITTED A MANUSCRIPT FOR PUBLICATION IN THE ON-DRUG DELIVERY JOURNAL. E.IMMUNOGENICITY: ENHANCED SC CONSORTIUM AWARENESS BY HIGHLIGHTING IMMUNOGENICITY SUB-TEAM ACTIVITIES AT THE IMMUNOGENICITY AND BIOASSAY SUMMIT, AUTHORED THE IMMUNOGENICITY PORTION OF "DEBUNKING THE MYTHS OF SC DELIVERY,- AND EXPECTS MANUSCRIPT SUBMISSION BEFORE YEAR-END. F.BIOAVAILABILITY: SUBMISSION OF "DEBUNKING THE MYTHS OF SC DELIVERY," DESCRIBING ADVANCEMENTS AND OPPORTUNITIES IN SC BIOAVAILABILITY, TO THE JOURNAL OF CONTROLLED RELEASE; A SECOND PUBLICATION, "PREDICTING HUMAN SUBCUTANEOUS BIOAVAILABILITY OF MONOCLONAL ANTIBODIES USING A NOVEL OPEN FLOW MICROPERFUSION (OFM) PORCINE MODEL," IS UNDER REVIEW. A.PATIENT PREFERENCE & EXPERIENCE: COMPLETED THE DESIGN AND DEVELOPMENT OF THE CONJOINT TOOL AND SURVEY ON PATIENT PREFERENCE FOR SUBCUTANEOUS DRUG DELIVERY; FIELDING IS COMPLETE WITH OVER 500 RESPONSES RECORDED FROM THE US, EU, AND JAPAN, AND ANALYSIS IS UNDERWAY. B.HIGH DOSE HIGH VOLUME: COMPLETED AN INDUSTRY-WIDE SURVEY ON "HARMONIZATION OF PAIN METHODOLOGIES FOR SC ADMINISTRATION-; DRAFT MANUSCRIPT "INTEGRATED CMC ROAD MAP FOR DEVELOPMENT OF HDHV PRODUCTS- AND THE "HDHV SELECTION CRITERIA MATRIX" ARE EXPECTED TO BE PUBLISHED IN 2026 FOLLOWING INTERNAL SC CONSORTIUM REVIEW. C.CLINICAL DESIGN & REGULATORY STRATEGY: PUBLISHED A CROSS-COMPANY SURVEY MANUSCRIPT ON CLINICAL AND REGULATORY STRATEGY IN THE JOURNAL OF CONTROLLED RELEASE AND CONDUCTED A WORKSHOP ON "DEVELOPMENT PATHWAYS AND CONSIDERATIONS FOR SUBCUTANEOUS BIOLOGIC FORMULATIONS" AT THE CRS 2025 ANNUAL MEETING & EXPOSITION IN PHILADELPHIA. D.SUSTAINABILITY: COMPLETED AND PRESENTED RESULTS OF THE INDUSTRY BENCHMARKING SURVEY AT MULTIPLE CONFERENCES THROUGHOUT THE YEAR, INCLUDING A POSTER PRESENTATION AT THE PDA UPS CONFERENCE IN VIENNA, AND SUBMITTED A MANUSCRIPT FOR PUBLICATION IN THE ON-DRUG DELIVERY JOURNAL. E.IMMUNOGENICITY: ENHANCED SC CONSORTIUM AWARENESS BY HIGHLIGHTING IMMUNOGENICITY SUB-TEAM ACTIVITIES AT THE IMMUNOGENICITY AND BIOASSAY SUMMIT, AUTHORED THE IMMUNOGENICITY PORTION OF "DEBUNKING THE MYTHS OF SC DELIVERY,- AND EXPECTS MANUSCRIPT SUBMISSION BEFORE YEAR-END. F.BIOAVAILABILITY: SUBMISSION OF "DEBUNKING THE MYTHS OF SC DELIVERY," DESCRIBING ADVANCEMENTS AND OPPORTUNITIES IN SC BIOAVAILABILITY, TO THE JOURNAL OF CONTROLLED RELEASE; A SECOND PUBLICATION, "PREDICTING HUMAN SUBCUTANEOUS BIOAVAILABILITY OF MONOCLONAL ANTIBODIES USING A NOVEL OPEN FLOW MICROPERFUSION (OFM) PORCINE MODEL," IS UNDER REVIEW.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(6) business league.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.

  3. Are donations tax-deductible? Caution.

    The IRS master file records contributions to this 501(c)(6) business league as not deductible.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since November 2022.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.